Navigation Links
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Date:7/15/2008

se rate (CR) of 41 percent. A CR means that after treatment with the TREANDA and rituximab combination, patients had no detectable evidence of disease. These responses were durable, with a median duration of 21 months overall (19 months for the mantle cell population). Additionally, the combination of TREANDA and rituximab was associated with progression-free survival (PFS) of 23 months overall and for patients with mantle cell lymphoma.

In this published study, the combination of both treatments was generally well tolerated. The most common adverse events in the trial included myelosuppression (a condition in which bone marrow activity is decreased), nausea, infection, fatigue, constipation, and diarrhea.

This combination study is one of three studies in patients with NHL that Cephalon submitted to the FDA in December 2007 requesting approval of TREANDA for the treatment of patients with indolent NHL who have progressed during or following treatment with rituximab or a rituximab-containing regimen. The other two studies evaluated the efficacy and safety of TREANDA as monotherapy in this patient population. In all three studies, patients treated with TREANDA had a high rate of response and a manageable side effect profile, with myelosuppression as the most common side effect. Cephalon anticipates a review decision on this application by the agency by October 31, 2008.

About Non-Hodgkin's Lymphoma

According to the American Cancer Society, an estimated 66,000 people in the United States will be diagnosed in 2008 with NHL. There are approximately 30 different types of NHL, which have been divided into two major categories: indolent (or slow growing) and aggressive. Indolent B-cell lymphoma and mantle cell lymphoma (one of the more aggressive sub-types) are difficult to treat because patients are prone to relapse after treatment.

About TREANDA

TREANDA has a unique chemical structure with two primary components, an alkylating gro
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
2. Complete Study Results Comparing CTIs OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
3. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
4. Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
5. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
8. Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
9. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
10. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
11. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... N.C. , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Medical Equipment, Inc. for the third straight year, ... Inc. 500|5000, an exclusive ranking of the nation,s ... comprehensive look at the most important segment of ... Pandora, Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and ...
(Date:8/21/2014)... 21, 2014  Seventy-one percent of Americans believe the abuse ... serious public health and safety issue in the ... released today by Repass & Partners, a Cincinnati ... understand the severity of the prescription medication abuse problem and ... very serious health situation facing our country," Rex Repass ...
(Date:8/21/2014)... PHILADELPHIA , Aug. 21, 2014  ACI ... platform for independent Data Monitoring Committees. ... to 30 percent over industry standard costs and ... an industry leader in committee services. ... member recruitment and contracting, charter development, statistical programming ...
Breaking Medicine Technology:Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2
... - Hospital Universitari Vall d,Hebron Research Institute in Barcelona ... an open label phase 2 study evaluating the overall ... treatment of cirrhosis of the liver and upper GI ... patients demonstrated that OCR-002 is well tolerated and provided ...
... (Nasdaq: MYL ) today announced that Mylan ... a settlement agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor ... connection with Mylan Specialty,s Abbreviated New Drug Application (ANDA) ... 0.63 mg/3 mL, 1.25 mg/3 mL and 1.25 mg/0.5mL. ...
Cached Medicine Technology:Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 2Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 3Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex® 2
(Date:8/22/2014)... New York (PRWEB) August 22, 2014 ... to be filed in U.S. courts on behalf ... due to their use of prescription low testosterone ... documents, a new claim was filed against Pfizer ... who allegedly suffered life-threatening heart issues due to ...
(Date:8/22/2014)... Prairie du Sac, Wisconsin (PRWEB) August 22, 2014 ... FasciaDerm® PFTape™ System for Plantar Fasciitis, an exciting new ... The product allows you to stay active while you ... per application. This is truly a new technology – ... patented and affordable. , FasciaDerm® PFTape™ System for ...
(Date:8/22/2014)... August 22, 2014 The improved access ... specifically in the developing world, has led to the ... number of deaths due to AIDS globally. However, despite ... number of new patients becoming affected by the virus ... being undertaken by all related organisations and stakeholders, by ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Back-to-school time provides ... that fits into the family schedules, an expert suggests. ... child,s school year can also be the start of ... Richards, a professor of kinesiology at the University of ... release. With kids, extracurricular activities likely to build ...
(Date:8/22/2014)... Dayton Children's Hospital broke ground on a ... a $141 million campus renewal. Renderings of ... to the public. , The new patient tower is ... a campus that meets the needs of patients, families and ... will embody Dayton Children’s unique patient care mission and offer ...
Breaking Medicine News(10 mins):Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:With Kids in School, Parents Can Work Out 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5
... Ultrasound and Management Practice Software to Support Advanced Diagnoses ... ... Oct. 21 South Carolina Veterinary,Specialists (SCVS), a leading regional ... Digital Practice(R) at its,new state-of-the-art facility in Columbia. The Eklin ...
... EXTON, Pa., Oct. 21 Isolagen(TM), Inc. (Amex:,ILE) ... in the Phase,II/III Study IT-A-008 investigating Isolagen Therapy(TM) ... scars. Further, approximately half of all,of the study ... the acne study will conclude in the first ...
... Is Safe And Active in Recurrent Ovarian Cancer; ... Oct. 21 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... results of the company,s proprietary polymer DACH,platinum prodrug, ... this week at a major international oncology conference ...
... reserve compensates for brain damage, study says , , TUESDAY, ... of education and a mentally demanding job may help ... according to an Italian study. , It included 242 ... 144 with no memory problems. People with mild cognitive ...
... players reach the base faster that way , , TUESDAY, Oct. ... slide head first or feet first during Wednesday,s first game ... a physicist instead of a coach. , The effectiveness of ... and factors like a baseball player,s center of gravity, explained ...
... risk, study finds , , TUESDAY, Oct. 21 (HealthDay News) -- ... the first time in a decade, particularly among middle-aged white ... we haven,t had as much focus on in terms of ... males, and there has been a lot of attention to ...
Cached Medicine News:Health News:South Carolina Veterinary Specialists Installs State-of-the-Art Eklin Digital Practice(R) Technology 2Health News:South Carolina Veterinary Specialists Installs State-of-the-Art Eklin Digital Practice(R) Technology 3Health News:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study 2Health News:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study 3Health News:Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 2Health News:Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008 3Health News:Job, Education May Buffer Against Dementia 2Health News:Head-First Slide a Heads-Up Play 2Health News:Suicide Rates Rise Among Baby Boomers 2Health News:Suicide Rates Rise Among Baby Boomers 3
Calibration plasmas for Assays of Low Molecular Weight Heparins (LMWH)using the Anti-Xa method on STA© Analyzers....
Control Plasma for Assays of Low MolecularWeight Heparins (LMWH) using Anti-Xa Method on STA© Analyzers....
PT, PTT, Fibrinogetn & TT Normal and Abnormal Controls...
ApolipoproteinA-1 & B Calibrator...
Medicine Products: